Athira Pharma, Inc. (ATHA)
After hours:
| Previous close | 3.3200 |
| Open | 3.3600 |
| Bid | 3.2600 x 100 |
| Ask | 3.3300 x 400 |
| Day's range | 3.2500 - 3.3750 |
| 52-week range | 1.3300 - 4.2980 |
| Volume | |
| Avg. volume | 145,572 |
| Market cap | 126.868M |
| Beta (5Y monthly) | 2.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.0500 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.27 |
ZacksAthira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
Athira (ATHA) completes dosing the last patient in the phase II/III LIFT-AD study on fosgonimeton for treating people with mild-to-moderate Alzheimer's disease. Stock gains.
GlobeNewswireAthira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the completion of dosing for the last patient in the Phase
Simply Wall St.retail investors who own 35% along with institutions invested in Athira Pharma, Inc. (NASDAQ:ATHA) saw increase in their holdings value last week
Key Insights The considerable ownership by retail investors in Athira Pharma indicates that they collectively have a...
